Moderna (MRNA) Change in Account Payables (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Account Payables data on file, last reported at -$120.0 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$120.0 million, up 23.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$56.0 million (down 171.79% YoY), and the FY2025 annual result was -$92.0 million, down 33.33% from the prior year.
• Change in Account Payables fell to -$120.0 million in Q1 2026 per MRNA's latest filing, from $22.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $179.0 million in Q3 2023 and troughed at -$303.0 million in Q1 2024.
• A 5-year average of -$1.6 million and a median of $21.0 million in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables soared 905.56% in 2022, then tumbled 234.29% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $151.0 million in 2022, then slumped by 86.09% to $21.0 million in 2023, then soared by 61.9% to $34.0 million in 2024, then slumped by 35.29% to $22.0 million in 2025, then tumbled by 645.45% to -$120.0 million in 2026.
• Business Quant data shows MRNA's Change in Account Payables at -$120.0 million in Q1 2026, $22.0 million in Q4 2025, and $89.0 million in Q3 2025.